Copyright © Inderes 2011 - present. All rights reserved.

Nanoform Finland

0.75 EUR

-0.79 %

3,693 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

-0.79 %
-20.17 %
-35.84 %
-29.19 %
-17.36 %
-36.81 %
-70.57 %
-89.97 %
-85.11 %

Nanoform Finland operates in the medical technology sector. The company specializes in research and development of nanoparticle technology used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. Customers consist of players in the global pharmaceutical industry, with the largest operations in the Nordic market. Nanoform Finland is headquartered in Helsinki.

Read more
Market cap
64.42M EUR
Turnover
205.45K EUR
Revenue
2.78M
EBIT %
-872.43 %
P/E
-
Dividend yield-%
-
Revenue and EBIT-%

Revenue M

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26.2
2026

Annual report '25

14.4
2026

General meeting '26

19.5
2026

Interim report Q1'26

ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
Now that’s some good mini- news, by the way. If that SC Nanotrastuzumab provides AUC, Cmax, and Tmax values in pigs equivalent to Herceptin HYLECTA, I would proceed with the assumption that there is also reason to expect similar results in humans. Now, I suppose it’s a matter of ...
2/12/2026, 4:54 PM
by jerej
15
Probably more info next Thursday. It’s possible we’ll slowly drift downwards until then, as biotech firms on the Helsinki exchange have been sold off quite heavily recently. Inderes Invitation to Nanoform’s Q4 and FY2025 Report Presentation - Inderes Nanoform Finland Plc | Press ...
yesterday
by jerej
10
Nanoform small is powerful Nanoform Finland Plc’s change negotiations have ended - Nanoform small is... Nanoform Finland Plc | Company Release | February 05, 2026… “As a result of the negotiations, 49 employees will be terminated. In addition, temporary part-time layoffs may be implemented...
2/5/2026, 6:11 AM
by Latupuikko
10
Nanoform small is powerful Nanoform - Subcutaneously administered Nanotrastuzumab matches performance of... Nanoform Finland Plc | Press Release | February 12, 2026…
2/12/2026, 7:33 AM
by Salvelinus
9
The company could certainly communicate a bit more promptly and clearly how things are progressing with nanoenzalutamide. After all, it is a very important matter in the minds of investors, as near-future cash flow assumptions and financing needs are so strongly linked to this. Silence...
yesterday
by JusaVaan
8
True, that’s how it was—the results were provided in connection with the earnings report. Perhaps it is possible that the results are already known but won’t be published until the Q4 report. However, I find that a bit strange from both a regulatory and company communication perspective...
1/30/2026, 10:47 PM
by Zeta
8
This subcutaneous formulation of biologics really has remarkable potential. I haven’t read the CMD transcripts yet, but I did flip through the slides earlier. There seem to be limited competitors regarding this technology at the moment. These slides from the CMD show those who have...
1/30/2026, 12:27 PM
by jerej
8
Read more on our forum
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.